Figure 4
Wegovy for subcutaneous (SC) administration is undergoing a Priority Review from the FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver condition tied to obesity and T2DM
Here, we examine the contribution of peptide agonist conformational plasticity to activation of the glucagon-like peptide 1 receptor (GLP-1R), an important clinical target
GLP-1 Examples A 2023 update 6 tells us there are currently seven GLP-1 receptor agonists, including: Exenatide Brand name: Byetta Dosage: twice-daily injection Exenatide extended-release Brand name: Bydureon Dosage: once-weekly injection Lixisenatide Brand name: Adlyxin Dosage: once-daily injection Liraglutide Brand names: Victoza and Saxenda Dosage: once-daily injection Dulaglutide Brand names: Trulicity Dosage: once-weekly injection Semaglutide Brand names: Ozempic and Wegovy Dosage: once-weekly injection Oral semaglutide Brand name: Rybelsus Dosage: once-daily injection We also can't overlook tirzepatide (branded as Mounjaro), which is the first agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
Additional safety considerations include caution in patients with severe gastroparesis, and a potential risk of diabetic retinopathy complications with rapid glucose improvement, particularly with semaglutide
Muscle, movement, and body composition Exercise is one of the most consistent signals in dementia-prevention research, but it should not be reduced to step counts
